Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin

G. Bacci, S. Ferrari, N. Delepine, F. Bertoni, P. Picci, M. Mercuri, P. Bacchini, A. Brach Del Prever, A. Tienghi, A. Comandone, M. Campanacci

Research output: Contribution to journalArticle

Abstract

Purpose: In osteosarcoma of the extremity, a strong correlation between chemotherapy-induced necrosis and prognosis has been reported. The aim of this study was to investigate the possible factors that influence histologic response to primary chemotherapy. Patients and Methods: In 272 patients with high-grade osteosarcoma of the extremity preoperatively treated with high- dose methotrexate (HDMTX), cisplatin (CDP), and doxorubicin (ADM), the histologic response to chemotherapy was evaluated and graded as complete (no viable tumor cells) or incomplete (persistence of viable tumor cells). Several factors, such as metastatic disease to the lung at diagnosis, sex, age, site and tumor volume, histologic subtype, serum alkaline phosphatase, lactate dehydrogenase (LDH), and methotrexate (MTX) pharmacokinetics were investigated to test their predictive significance on histologic response. Results: Fifty-one patients with localized disease (20.6%) and none of the 25 patients with metastatic disease at presentation had a complete histologic response (P = .006). After multivariate analysis, performed on patients with localized disease only, MTX serum peak (≤700 μmol/L) and histologic subtype were proven to be significant predictive factors of histologic response. A complete response was seen in 28.8% of patients with 700 μmol/L or greater MTX serum levels and in 9.9% of those patients with lower levels (P = .001). The chondroblastic subtype was less responsive (6.1% of complete response), compared with the osteoblastic (16.3%), fibroblastic (33.3%), and telangiectatic (42.3%). Conclusion: Patients with metastatic osteosarcoma and localized chondroblastic osteosarcoma have a reduced chemosensitivity to primary chemotherapy with MTX, CDP, and ADM. MTX serum peak significantly influences tumor necrosis. A dose adaptation of MTX is recommended to obtain a serum peak of 700 μmol/L or greater when MTX is infused in 6 hours.

Original languageEnglish
Pages (from-to)658-663
Number of pages6
JournalJournal of Clinical Oncology
Volume16
Issue number2
Publication statusPublished - Feb 1998

Fingerprint

Osteosarcoma
Methotrexate
Doxorubicin
Cisplatin
Extremities
Drug Therapy
Cytidine Diphosphate
Serum
Necrosis
Neoplasms
Tumor Burden
L-Lactate Dehydrogenase
Lung Diseases
Alkaline Phosphatase
Multivariate Analysis
Pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity : Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. / Bacci, G.; Ferrari, S.; Delepine, N.; Bertoni, F.; Picci, P.; Mercuri, M.; Bacchini, P.; Brach Del Prever, A.; Tienghi, A.; Comandone, A.; Campanacci, M.

In: Journal of Clinical Oncology, Vol. 16, No. 2, 02.1998, p. 658-663.

Research output: Contribution to journalArticle

Bacci, G, Ferrari, S, Delepine, N, Bertoni, F, Picci, P, Mercuri, M, Bacchini, P, Brach Del Prever, A, Tienghi, A, Comandone, A & Campanacci, M 1998, 'Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin', Journal of Clinical Oncology, vol. 16, no. 2, pp. 658-663.
Bacci, G. ; Ferrari, S. ; Delepine, N. ; Bertoni, F. ; Picci, P. ; Mercuri, M. ; Bacchini, P. ; Brach Del Prever, A. ; Tienghi, A. ; Comandone, A. ; Campanacci, M. / Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity : Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 2. pp. 658-663.
@article{f8daf00171e24dbc98cce72199ef6730,
title = "Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin",
abstract = "Purpose: In osteosarcoma of the extremity, a strong correlation between chemotherapy-induced necrosis and prognosis has been reported. The aim of this study was to investigate the possible factors that influence histologic response to primary chemotherapy. Patients and Methods: In 272 patients with high-grade osteosarcoma of the extremity preoperatively treated with high- dose methotrexate (HDMTX), cisplatin (CDP), and doxorubicin (ADM), the histologic response to chemotherapy was evaluated and graded as complete (no viable tumor cells) or incomplete (persistence of viable tumor cells). Several factors, such as metastatic disease to the lung at diagnosis, sex, age, site and tumor volume, histologic subtype, serum alkaline phosphatase, lactate dehydrogenase (LDH), and methotrexate (MTX) pharmacokinetics were investigated to test their predictive significance on histologic response. Results: Fifty-one patients with localized disease (20.6{\%}) and none of the 25 patients with metastatic disease at presentation had a complete histologic response (P = .006). After multivariate analysis, performed on patients with localized disease only, MTX serum peak (≤700 μmol/L) and histologic subtype were proven to be significant predictive factors of histologic response. A complete response was seen in 28.8{\%} of patients with 700 μmol/L or greater MTX serum levels and in 9.9{\%} of those patients with lower levels (P = .001). The chondroblastic subtype was less responsive (6.1{\%} of complete response), compared with the osteoblastic (16.3{\%}), fibroblastic (33.3{\%}), and telangiectatic (42.3{\%}). Conclusion: Patients with metastatic osteosarcoma and localized chondroblastic osteosarcoma have a reduced chemosensitivity to primary chemotherapy with MTX, CDP, and ADM. MTX serum peak significantly influences tumor necrosis. A dose adaptation of MTX is recommended to obtain a serum peak of 700 μmol/L or greater when MTX is infused in 6 hours.",
author = "G. Bacci and S. Ferrari and N. Delepine and F. Bertoni and P. Picci and M. Mercuri and P. Bacchini and {Brach Del Prever}, A. and A. Tienghi and A. Comandone and M. Campanacci",
year = "1998",
month = "2",
language = "English",
volume = "16",
pages = "658--663",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity

T2 - Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin

AU - Bacci, G.

AU - Ferrari, S.

AU - Delepine, N.

AU - Bertoni, F.

AU - Picci, P.

AU - Mercuri, M.

AU - Bacchini, P.

AU - Brach Del Prever, A.

AU - Tienghi, A.

AU - Comandone, A.

AU - Campanacci, M.

PY - 1998/2

Y1 - 1998/2

N2 - Purpose: In osteosarcoma of the extremity, a strong correlation between chemotherapy-induced necrosis and prognosis has been reported. The aim of this study was to investigate the possible factors that influence histologic response to primary chemotherapy. Patients and Methods: In 272 patients with high-grade osteosarcoma of the extremity preoperatively treated with high- dose methotrexate (HDMTX), cisplatin (CDP), and doxorubicin (ADM), the histologic response to chemotherapy was evaluated and graded as complete (no viable tumor cells) or incomplete (persistence of viable tumor cells). Several factors, such as metastatic disease to the lung at diagnosis, sex, age, site and tumor volume, histologic subtype, serum alkaline phosphatase, lactate dehydrogenase (LDH), and methotrexate (MTX) pharmacokinetics were investigated to test their predictive significance on histologic response. Results: Fifty-one patients with localized disease (20.6%) and none of the 25 patients with metastatic disease at presentation had a complete histologic response (P = .006). After multivariate analysis, performed on patients with localized disease only, MTX serum peak (≤700 μmol/L) and histologic subtype were proven to be significant predictive factors of histologic response. A complete response was seen in 28.8% of patients with 700 μmol/L or greater MTX serum levels and in 9.9% of those patients with lower levels (P = .001). The chondroblastic subtype was less responsive (6.1% of complete response), compared with the osteoblastic (16.3%), fibroblastic (33.3%), and telangiectatic (42.3%). Conclusion: Patients with metastatic osteosarcoma and localized chondroblastic osteosarcoma have a reduced chemosensitivity to primary chemotherapy with MTX, CDP, and ADM. MTX serum peak significantly influences tumor necrosis. A dose adaptation of MTX is recommended to obtain a serum peak of 700 μmol/L or greater when MTX is infused in 6 hours.

AB - Purpose: In osteosarcoma of the extremity, a strong correlation between chemotherapy-induced necrosis and prognosis has been reported. The aim of this study was to investigate the possible factors that influence histologic response to primary chemotherapy. Patients and Methods: In 272 patients with high-grade osteosarcoma of the extremity preoperatively treated with high- dose methotrexate (HDMTX), cisplatin (CDP), and doxorubicin (ADM), the histologic response to chemotherapy was evaluated and graded as complete (no viable tumor cells) or incomplete (persistence of viable tumor cells). Several factors, such as metastatic disease to the lung at diagnosis, sex, age, site and tumor volume, histologic subtype, serum alkaline phosphatase, lactate dehydrogenase (LDH), and methotrexate (MTX) pharmacokinetics were investigated to test their predictive significance on histologic response. Results: Fifty-one patients with localized disease (20.6%) and none of the 25 patients with metastatic disease at presentation had a complete histologic response (P = .006). After multivariate analysis, performed on patients with localized disease only, MTX serum peak (≤700 μmol/L) and histologic subtype were proven to be significant predictive factors of histologic response. A complete response was seen in 28.8% of patients with 700 μmol/L or greater MTX serum levels and in 9.9% of those patients with lower levels (P = .001). The chondroblastic subtype was less responsive (6.1% of complete response), compared with the osteoblastic (16.3%), fibroblastic (33.3%), and telangiectatic (42.3%). Conclusion: Patients with metastatic osteosarcoma and localized chondroblastic osteosarcoma have a reduced chemosensitivity to primary chemotherapy with MTX, CDP, and ADM. MTX serum peak significantly influences tumor necrosis. A dose adaptation of MTX is recommended to obtain a serum peak of 700 μmol/L or greater when MTX is infused in 6 hours.

UR - http://www.scopus.com/inward/record.url?scp=0031943038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031943038&partnerID=8YFLogxK

M3 - Article

C2 - 9469355

AN - SCOPUS:0031943038

VL - 16

SP - 658

EP - 663

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -